If you go to another bispecifics meeting, you’re going to see the same formats. The same presentations.
You’ve asked us to take it the next level. You want to know you can manufacture your bispecific. That it has stability, and the shelf life of a monoclonal antibody. You want a drug that will go into patients, and perform.
The time has come when we move beyond engineering and start thinking about bispecific molecules as drug-like molecules. And ask the basic question ‘what will make a drug?’ For instance issues around target selection and biology, format suitability, pharmacokinetics, stability, safety and manufacturability.
But of most importance is clinical performance. Your only way of accurately assessing the medical and commercial potential of specific formats.
Attend the Bispecific Antibody Summit, and you’ll get all of this and more.
If you’re already embedded in the field, expect to leave armed with dozens of new ideas and approaches that you can apply to your own bispecific development program.
And if you’re still investigating whether to enter the field, you’ll cut through the hype and immediately understand the commercial realities of developing a bispecific. First-hand from those on the front line.
When you’re in such intense competition, it’s often difficult to reach out and make new connections with others who are experiencing the same difficulties.
Which makes the way you spend your time at this conference crucial.
Not only that, the Bispecific Antibody Summit is also a huge opportunity to get the answers you need to tailored, specific questions. By meeting those who are going through the same challenges.
Some of that happens in the conference room. And in the pre-conference workshops, when you’ll have the chance to bring your burning questions into a wider discussion.
But most happens informally, during breaks and networking sessions.
The Bispecific Antibody Summit has over 10 hours of dedicated networking time built into the agenda, in the form of Speed Networking, MasterMind Groups, networking lunches and a relaxed, informal drinks reception at the end of day one.
"A very good conference, with a good diversity of talks" Laurence Fayadat-Dilman, Senior Principal Scientist, Merck & Co
"Provides an excellent overview of the field, and excellent networking opportunities" Andreas Menrad, CSO, Ablynx
"The speed networking and round table meetings were GREAT!" Josefine Persson, Senior Manager, Genentech
"My first time doing the speed networking and MasterMind Groups, and I found it very effective" Diego Ellerman, Senior Research Assistant, Genentech
"A well organized conference on bispecifics covering all areas of drug discovery and development" Surendran Rajendran, Senior Research Investigator, Bristol-Myers Squibb
"Fantastic speakers and very focussed!" David Poon, Associate Director, Business Development, Zymeworks
"A good opportunity to improve my fundamental understanding of the bispecifics field" Shigeo Hirasawa, Senior Researcher, Ajimoto Co.
"An excellent opportunity to learn about the latest developments in the bispecific antibody field" Rajkumar Ganesan, Principal Scientist, Boehringer Ingelheim
"Very informative, educational and enlightening conference for scientists who have different levels of experiences in bispecifics" Xinwei Wang, Associate Scientist II, MedImmune
"Provides an excellent overview of the bispecifics field, and brings people of the field together for stimulating discussions and future research" Florian Schelter, Scientist, Roche
"An excellent summit to hear about technology updates and current issues within the field of bispecific antibodies" Steve Comeau, Staff Scientist, Dyax Corp
"Very interesting overview of bispecific technologies and therapeutics" Roberto Sommavilla, Investigator - Bispecifics Platform, Novartis
"Highly relevant scientific discussion, and great networking opportunities" Surjit Dixit, CSO, Zymeworks
"Great speakers, great networking, great and stimulating discussions!" Ercole Rao, Group Leader, Sanofi
"A highly interactive conference with excellent presentations and exciting data" Hilde Reverts, Senior Research Fellow, Ablynx
"Technical experts in the field of bispecifics coming together to discuss their successes" Leah Helvering, Senior Scientist, Eli Lilly
"An excellent overview of established and emerging platforms for the generation of highly complex biologics suited to target biology" Boehringer Ingelheim
"Good blend of science, medicine and engineering - excellent networking opportunities" Crystal Bioscience